-
Posted by
Two Blokes Apr 24 -
Filed in
Stock
-
4 views
Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN and Pathos AI. The multi-year deal focuses on building a multimodal AI-driven foundation model for oncology, using TempusAI's de-identified oncology data.
